Szerző szerinti böngészés "Cheng, Yu-Fan"

Megjelenítve 1 - 2 (Összesen 2)
  • Nincs kép
    TételKorlátozottan hozzáférhető
    New Perspective in Treatment of Community-Acquired Pneumonia
    Cheng, Yu-Fan; Brugós, László; Department of Pulmonology; DE--Általános Orvostudományi Kar; Lieber, Attila; Timea, Durzak; Debreceni Egyetem::Általános Orvostudományi Kar::Tüdőgyógyászati Klinika; Debreceni Egyetem::Általános Orvostudományi Kar::Infektológiai és Gyermekimmunológiai Tanszék
    Pneumonia has been one of the top contenders for the leading cause of death for decades. Due to vague symptoms and unreliable laboratory examinations, treatment of community-acquired pneumonia relies on empiric use of antibiotics more than any other diseases. However, the high demand for antibiotics lead to the rise of multidrug-resistant pathogens; thus, increasing the difficulty of treatment of pneumonia. Future of treatment of community-acquired pneumonia will be dependent on two things. First, current restriction and regulation of antibiotics to slow down the development of microbial drug resistance. Second, encourage development of new medical and laboratory technologies and their applications. These new technologies can provide not only new methods of microbial termination, but also aid the diagnosis of pneumonia to gain earlier and with more precise drug treatment.
  • Nincs kép
    TételKorlátozottan hozzáférhető
    New Perspective in Treatment of Community-Acquired Pneumonia
    Cheng, Yu-Fan; Brugós, László; Debreceni Egyetem::Általános Orvostudományi Kar::Tüdőgyógyászati Klinika; DE--Általános Orvostudományi Kar; Lieber, Attila; Timea, Durzak; Debreceni Egyetem::Általános Orvostudományi Kar::Tüdőgyógyászati Klinika; Debreceni Egyetem::Általános Orvostudományi Kar::Infektológiai és Gyermekimmunológiai Tanszék
    Pneumonia has been one of the top contenders for the leading cause of death for decades. Due to vague symptoms and unreliable laboratory examinations, treatment of community-acquired pneumonia relies on empiric use of antibiotics more than any other diseases. However, the high demand for antibiotics lead to the rise of multidrug-resistant pathogens; thus, increasing the difficulty of treatment of pneumonia. Future of treatment of community-acquired pneumonia will be dependent on two things. First, current restriction and regulation of antibiotics to slow down the development of microbial drug resistance. Second, encourage development of new medical and laboratory technologies and their applications. These new technologies can provide not only new methods of microbial termination, but also aid the diagnosis of pneumonia to gain earlier and with more precise drug treatment.